Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
antidepressant |
| gptkbp:activeIngredient |
gptkb:paroxetine
|
| gptkbp:ATCCode |
N06AB05
|
| gptkbp:brand |
gptkb:Paxil
gptkb:Seroxat |
| gptkbp:contraindication |
concurrent use with MAO inhibitors
|
| gptkbp:drugClass |
selective serotonin reuptake inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aropax
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:marketedIn |
gptkb:Australia
|
| gptkbp:pregnancyCategory |
gptkb:D_(Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
weight gain drowsiness dry mouth sexual dysfunction |
| gptkbp:usedFor |
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder gptkb:panic_disorder gptkb:post-traumatic_stress_disorder gptkb:social_anxiety_disorder gptkb:major_depressive_disorder anxiety disorders |
| gptkbp:bfsParent |
gptkb:Paxil
gptkb:Seroxat gptkb:Paroxetine |
| gptkbp:bfsLayer |
7
|